Allergy Asthma Immunol Res.  2013 Jan;5(1):55-58. 10.4168/aair.2013.5.1.55.

Clinical Features of Immediate Hypersensitivity to Isopropylantipyrine

• Hwang EK
• Nam YH
• Jin HJ
• Shin YS
• Ye YM
• Park HS

• KMID: 2167007
• DOI: http://doi.org/10.4168/aair.2013.5.1.55

Abstract

Hypersensitivities induced by isopropylantipyrine (IPA), a pyrazolone derivative within the wider family of non-steroidal anti-inflammatory drugs (NSAIDs), are rarely reported. We characterized the clinical features of 12 patients with IPA-induced hypersensitivity. Twelve patients with immediate hypersensitivity to IPA were enrolled and classified into two groups: group I, consisting of eight patients (66.7%) with selective hypersensitivity; and group II, consisting of four patients (33.3%) showing cross-intolerance to other NSAIDs. Skin prick and intradermal and oral provocation tests with IPA were performed. To confirm selective hypersensitivity, an aspirin oral provocation test was also conducted. The most common manifestations were cutaneous reactions (91.7%), followed by anaphylaxis (66.7%), respiratory (41.7%), ocular (16.7%), and gastrointestinal reactions (16.7%). The median age and the median age at onset were 34.5 (range, 23-55) years and 28.0 (range, 7-47) years, respectively. In both groups I and II, all patients showed negative responses to skin prick testing, whereas only two patients in group I were positive in response to intradermal IPA tests. The response time after drug exposure was shorter in group I than in group II. Here, we report on two types of IPA hypersensitivity: selective and cross-intolerant NSAID hypersensitivity. An immediate IgE-mediated reaction may be involved in patients with selective hypersensitivity, whereas a cyclooxygenase-1-related inhibition mechanism may be a responsible mechanism for the patients with cross-intolerance to multiple NSAIDs.

Keyword

Drug hypersensitivity; immediate hypersensitivity; isopropylantipyrine; pyrazolone

MeSH Terms

Anaphylaxis
Anti-Inflammatory Agents, Non-Steroidal
Aspirin
Drug Hypersensitivity
Humans
Hypersensitivity
Hypersensitivity, Immediate
Pyrazolones
Reaction Time
Skin
Anti-Inflammatory Agents, Non-Steroidal
Aspirin
Pyrazolones

Reference

1. Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F, Ebner H, Ebner C. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol. 2003. 111:882–888.

2. Kowalski ML, Woszczek G, Bienkiewicz B, Mis M. Association of pyrazolone drug hypersensitivity with HLA-DQ and DR antigens. Clin Exp Allergy. 1998. 28:1153–1158.

3. Zhu D, Becker WM, Schulz KH, Schubeler K, Schlaak M. Detection of IgE antibodies specific for 1-phenyl-2,3-dimethyl-3-pyrazoline-5-one by RAST: a serological diagnostic method for sensitivity to pyrazoline drugs. Asian Pac J Allergy Immunol. 1992. 10:95–101.

4. Choi JH, Shin YS, Suh YJ, Suh CH, Nahm DH, Park HS. Two cases of hypersensitivity to isopropylantipyrine. J Asthma Allergy Clin Immunol. 2004. 24:137–140.

5. Lee YJ, Lee YW, Park JW, Hong CS. A Case of Propyphenazone induced asthma without aspirin sensitivity. Korean J Asthma Allergy Clin Immunol. 2006. 26:318–321.

6. Kowalski ML, Bienkiewicz B, Woszczek G, Iwaszkiewicz J, Poniatowska M. Diagnosis of pyrazolone drug sensitivity: clinical history versus skin testing and in vitro testing. Allergy Asthma Proc. 1999. 20:347–352.

7. Doña I, Blanca-López N, Cornejo-García JA, Torres MJ, Laguna JJ, Fernández J, Rosado A, Rondón C, Campo P, Agúndez JA, Blanca M, Canto G. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011. 41:86–95.

8. Rew SY, Koh YI, Shin HY, Park SH, Ryu SH, Kim HN, Kim MS, Chun SW. Reporting and clinical features of adverse drug reactions from a single university hospital. Korean J Asthma Allergy Clin Immunol. 2011. 31:184–191.

9. Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res. 2011. 3:3–10.

10. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, Bousquet P, Celik G, Demoly P, Gomes ER, Niżankowska-Mogilnicka E, Romano A, Sanchez-Borges M, Sanz M, Torres MJ, De Weck A, Szczeklik A, Brockow K. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy. 2011. 66:818–829.

11. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008. 128:35–44.

12. Quiralte J, Blanco C, Castillo R, Ortega N, Carrillo T. Anaphylactoid reactions due to nonsteroidal antiinflammatory drugs: clinical and cross-reactivity studies. Ann Allergy Asthma Immunol. 1997. 78:293–296.

13. Canto MG, Andreu I, Fernandez J, Blanca M. Selective immediate hypersensitivity reactions to NSAIDs. Curr Opin Allergy Clin Immunol. 2009. 9:293–297.

14. Romano A, Torres MJ, Castells M, Sanz ML, Blanca M. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011. 127:S67–S73.

15. Gómez E, Blanca-Lopez N, Torres MJ, Requena G, Rondon C, Canto G, Blanca M, Mayorga C. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Allergy. 2009. 39:1217–1224.

16. Sanz ML, Gamboa P, de Weck AL. A new combined test with flowcytometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol. 2005. 136:58–72.